Does the Piperacillin Minimum Inhibitory Concentration for Pseudomonas aeruginosa Influence Clinical Outcomes of Children With Pseudomonal Bacteremia?

Background. The Clinical and Laboratory Standards Institute (CLSI) recently elected to adjust the previous piperacillin susceptibility breakpoint of ≤64 µg/mL against Pseudomonas aeruginosa to ≤16 µg/mL, based largely on pharmacokinetic–pharmacodynamic (PK–PD) modeling studies. Data on whether PK–PD...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tamma, Pranita D., Turnbull, Alison E., Milstone, Aaron M., Hsu, Alice J., Carroll, Karen C., Cosgrove, Sara E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2012
Témata:
Articles and Commentaries
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657512/
https://ncbi.nlm.nih.gov/pubmed/22696019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis545
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky